Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs

A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be relevant for treating metastatic cancer. This is because actionable DNA errors remain remarkably stable over time, despite treatment with drugs. This discovery was made by Dutch researchers in a study led by the Netherlands Cancer Institute. The researchers used data from the Hartwig Medical Database for their research. They published their findings on August 9 online in the scientific journal Nature Medicine.
More information
- Publication in Nature: Joris van de Haar et al, ‘Limited evolution of the actionable metastatic cancer genome under therapeutic pressure’
- Read the complete article on the Antoni van Leeuwenhoek website
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Video voor treating physicians and pathologists about one-time analysis of the entire tumor DNA
- More information about WGS and the extensive DNA test for Cancer Diagnostics: OncoAct.nl
All news
Also read

Whole genome sequencing to improve individual cancer treatment in Finland
Since August 2019, Docrates, a private cancer center in Finland, uses the whole genome sequencing test from Hartwig Medical Foundation to …

Whole genome sequencing is reliable, has added value, and can be embedded perfectly into everyday pathology diagnostics
Source: website Netherlands Cancer Institute With the rapidly expanding tableau of (increasingly tumor-agnostic) targeted therapies, genome-driven cancer care has become …

Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …

In our profession, we need to know everything about the patient, but we also want to know as much as possible about the patient’s tumor.